17. Januar 2024
Vendor-Management in klinischen Studien, die Bedeutung des risikobasierten Ansatzes und die Notwendigkeit einer kontinuierlichen Oversight.
It is great to have you here. Please let me ask for your approval.
In order to provide you with the best possible website experience, I ask you to accept the settings for cookies. We would like to optimize our website for you in the future by analyzing user behavior.
Necessary CookiesWe use these cookies for the smooth operation of the website. This dialog box you're reading sets a cookie. Detailed information can be found in our privacy policy under point 4. Use of cookies on our site.
In addition, the following other cookies may be used on this website:
This cookie transmits anonymous data to Google Analytics.
You can adjust your decision at any time by navigating to Cookie settings.